Lanadelumab

Phase 3

Amgen Inc. (AMGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

22 competitors in COVID-19

MRNACOVID vaccine (updated)

Drug Information

Target Indication

COVID-19

Clinical Trial

NCT04590586

Last updated: 1/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA11/22/2018

Takhzyro

Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.

OrphanAccelerated

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

TarlatamabPhase 3

Small Cell Lung Cancer

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

Etanercept LiquidPhase 3

Rheumatoid Arthritis

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts